PIK3CA and neoplasm: As there is evidence that inhibition of the PI3K pathway may prevent resistance to chemotherapy and potentiate its efficacy, the combination of PI3K inhibitors with MCT affecting angiogenesis, immune response, and tumor cells via direct cytotoxicity may represent a new promising approach for the treatment of MBC, aiming to achieve synergistic effects, overcome drug resistance, or decrease the drug dose and toxicities.